AHA March 26 submitted comments on a discussion draft of the SUSTAIN 340B Act, legislation proposed in the Senate to clarify Congress’ intent in creating the 340B program and protect 340B providers from egregious behavior by drug companies, insurers and pharmacy benefit managers.  

“Their unlawful and pernicious practices have collectively undermined the 340B program and harmed patient care,” AHA wrote. “At the same time, we have concerns regarding other aspects of this discussion draft that should be better aligned to reflect the operational realities that 340B hospitals face every day. Therefore, our comments primarily focus on how Congress can ensure that the 340B program continues to benefit patients and communities, while protecting against any unnecessary harm or burden that would jeopardize patient care.” 

Related News Articles

Headline
A Louisiana district court Sept. 30 upheld a state law prohibiting drug companies from denying Louisiana hospitals 340B discounts for drugs dispensed at…
Headline
Johnson & Johnson Sept. 30 notified the Health Resources and Services Administration that it is ceasing implementation of its proposed 340B rebate model.…
Headline
The Health Resources and Services Administration Sept. 27 sent a final warning letter to Johnson & Johnson urging the company to inform the agency by…
Headline
The House Energy and Commerce Committee Sept. 18 advanced legislation on expiring telehealth and hospital-at-home flexibilities. The AHA supported the passage…
Headline
“As pharmaceutical companies throw stone after stone at the 340B program, they should beware of their own glass house. Their complaints ring hollow when it is…
Headline
The Health Resources and Services Administration Sept. 17 told Johnson & Johnson that the company’s publicly announced plans to implement a 340B rebate…